李峻岭, 储大同. 康莱特治疗肺癌研究进展[J]. 中国肿瘤临床, 2012, 39(16): 1139-1142. DOI: 10.3969/j.issn.1000-8179.2012.16.001
引用本文: 李峻岭, 储大同. 康莱特治疗肺癌研究进展[J]. 中国肿瘤临床, 2012, 39(16): 1139-1142. DOI: 10.3969/j.issn.1000-8179.2012.16.001
Junling LI, Datong CHU. A Review of Kanglaite Treatment for Non-small Cell Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(16): 1139-1142. DOI: 10.3969/j.issn.1000-8179.2012.16.001
Citation: Junling LI, Datong CHU. A Review of Kanglaite Treatment for Non-small Cell Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(16): 1139-1142. DOI: 10.3969/j.issn.1000-8179.2012.16.001

康莱特治疗肺癌研究进展

A Review of Kanglaite Treatment for Non-small Cell Lung Cancer

  • 摘要: 康莱特注射液的成分为注射用薏苡仁油, 中医的功能主治为益气养阴, 消肿散结。在临床上单用或与化疗联合, 主要用于晚期非小细胞肺癌的治疗。研究显示康莱特注射液与常规疗法联合治疗非小细胞肺癌, 可提高临床疗效, 减轻不良反应, 稳定并改善患者的生活质量。

     

    Abstract: Kanglaite (KLT) injection, composed of coix seed oil, functions by supplementing qi and nourishing yin, which reduces swelling and eliminates stagnation in traditional Chinese medicine. KLT injection has been used mainly in the clinical treatment of advanced-stage non-small cell lung cancer, whether alone or in combination with chemotherapy. Studies confirmed that KLT injection combined with chemotherapy or targeted therapy for non-small cell lung cancer patients can enhance the clinical efficacy, reduce side effects, and improve the patients' quality of life.

     

/

返回文章
返回